EPRX – eupraxia pharmaceuticals inc. (US:NASDAQ)
Stock Stats
News
Eupraxia Pharmaceuticals (EPRX) is now covered by William Blair. They set an "outperform" rating on the stock.
Eupraxia Pharmaceuticals (EPRX) was downgraded by Zacks Research from "hold" to "strong sell".
Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis [Yahoo! Finance]
Eupraxia Pharmaceuticals (EPRX) had its price target lowered by HC Wainwright from $12.00 to $11.00. They now have a "buy" rating on the stock.
Yahoo Finance [Yahoo! Finance]
Form 6-K EUPRAXIA PHARMACEUTICALS For: Mar 17
Form SCHEDULE 13D/A EUPRAXIA PHARMACEUTICALS Filed by: Freedman Joseph S.
Form 40-F EUPRAXIA PHARMACEUTICALS For: Dec 31
Form 6-K EUPRAXIA PHARMACEUTICALS For: Feb 23
Form 6-K EUPRAXIA PHARMACEUTICALS For: Feb 20
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.